NCT02692599CompletedPhase 3
A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants
Sinovac (Dalian) Vaccine Technology Co., Ltd.1 site in 1 country1,150 target enrollmentStarted: January 1, 2016Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 1,150
- Locations
- 1
- Primary Endpoint
- The seroconversion rates (SCRs) of susceptible subjects in each group
Study Overview
Brief Summary
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.
Detailed Description
This study is a randomized, blind, single-center, controlled phase III clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control vaccine is a commercialized live attenuated mumps vaccine manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd. All participants are healthy infants between 8 - 18 months old, and will be randomly assigned into experimental group or control group in the ratio 1:1.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 8 Months to 18 Months (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy volunteer between 8 - 18 months old;
- •Proven legal identity;
- •Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study;
- •Complying with the requirement of the study protocol;
Exclusion Criteria
- •Axillaty temperature > 37.0 °C;
- •Any significant abnormity of heart, lung, liver, spleen, lymph nodes, or pharynx;
- •Acute disease or acute stage of chronic disease within 7 days prior to study entry;
- •Prior vaccination with mumps vaccine or with history of mumps infection;
- •History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) about vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;
- •Receipt of any of the following products:
- •Any subunit vaccine or inactivated vaccine within 14 days prior to study entry;
- •Any live attenuated vaccine within 28 days prior to study entry;
- •Any other investigational medicine(s) within 30 days prior to study entry;
- •Blood product (e.g., immunoglobulin) within 3 months prior to study entry;
- •Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry;
- •Epilepsy (except febrile seizures), history of seizures or convulsions, or a family history of mental illness;
- •Autoimmune disease or immunodeficiency;
- •Congenital malformation, developmental disorders, or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders;
- •Severe malnutrition;
- •Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities);
- •Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
- •Participants with the following conditions between day 0 - 28 of this study would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS):
- •Receipt of any other investigational or unregistered product (drug or vaccine);
- •Receipt of immunosuppressant (corticosteroid dosage that equivalent to or above 0.5 mg prednisone/kg weight/day) for > 14 days consecutively, except for inhalant or locally administrated corticosteroid;
- •Receipt of immunoglobulin and/or blood product;
- •Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);
Arms & Interventions
Experimental Group
Experimental
- Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
- Intervention: investigational live attenuated mumps vaccine;
Intervention: investigational live attenuated mumps vaccine (Biological)
Control Group
Active Comparator
- Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
- Intervention: control live attenuated mumps vaccine;
Intervention: control live attenuated mumps vaccine (Biological)
Outcomes
Primary Outcomes
The seroconversion rates (SCRs) of susceptible subjects in each group
Time Frame: 28 days
Subjects whose pre-immune HI antibody level \< 1:2 are considered susceptible; among these subjects, those with post-immune HI antibody level ≥ 1:2 are considered seroconverted.
Secondary Outcomes
- The overall SCRs of each group(28 days)
- The incidences of adverse events (AEs) of each group(28 days)
- The incidences of serious adverse events (SAEs) of each group(28 days)
- The post-immune geometric mean titers (GMTs) of susceptible subjects in each group(28 days)
- The overall post-immune GMTs of each group(28 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsMumpsNCT05065177Sinovac Research and Development Co., Ltd.1,140
Completed
Phase 3
A Blind, Randomized and Controlled Study of Live Attenuated Varicella VaccinesVaricellaNCT02981836Sinovac (Dalian) Vaccine Technology Co., Ltd.5,997
Completed
Phase 4
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineMumpsNCT04364399Sinovac (Dalian) Vaccine Technology Co., Ltd.920
Completed
Phase 1
A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and ChildrenVaricellaNCT02965404Sinovac (Dalian) Vaccine Technology Co., Ltd.270
Withdrawn
Phase 2
A Phase II Study of H56:IC31 in Healthy AdolescentsTuberculosis InfectionNCT03265977Aeras